REG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Exercise of options and PDMR dealing
06/09/2024 17:15
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240906:nRSF3079Da&default-theme=true
RNS Number : 3079D MaxCyte, Inc. 06 September 2024
MaxCyte, Inc.
("MaxCyte" or the "Company")
Exercise of options and PDMR dealing
ROCKVILLE, MD, September 6, 2024: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT),
a leading, cell-engineering focused company providing enabling platform
technologies to advance the discovery, development, and commercialization of
next-generation cell therapeutics and to support innovative, cell-based
research, announces that between 3 September 2024 and 4 September 2024, as per
a filing lodged with the U.S. Securities and Exchange Commission, Stanley
Erck, a Non-Executive Director of the Company, exercised options over 47,689
shares of common stock of $0.01 of the Company ("Common Stock") ("Exercise")
in aggregate. The 47,689 new shares of Common Stock were issued pursuant to
the Company's existing its block admission facility and were sold by Stanley
Erck at a price range between $3.900 and $4.300 per Common Stock ("Sale").
The sold shares represent approximately 6.9% of Stanley Erck's total equity
and option holdings in the Company's stock capital, respectively.
Following the Exercise and Sale, Stanley Erck holds 247,751 shares of Common
Stock representing 0.2% of the issued stock capital of the Company. Following
the Exercise, Stanley Erck holds a further 371,879 options over Common Stock
and 21,367 restricted stock units.
The sales and option exercises were effected pursuant to a Rule 10b5-1 trading
plan adopted by Stanley Erck on 12 March 2024 relating solely to the sale of
shares acquired from exercise of options that expire on 11 November 2024.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group +1 415-937-5400
David Deuchler, CFA ir@maxcyte.com (mailto:ir@maxcyte.com)
Nominated Adviser and Joint Corporate Broker
Panmure Liberum +44 (0)20 7886 2500
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
UK IR Adviser +44 (0)203 709 5700
ICR Consilium maxcyte@consilium-comms.com (mailto:maxcyte@consilium-comms.com)
Mary-Jane Elliott
Chris Welsh
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize the potential of
cells to improve patients' lives. We have spent more than 20 years honing our
expertise by building best-in-class platforms, perfecting the art of the
transfection workflow, and venturing beyond today's processes to innovate
tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow
Electroporation® technology, has been designed to support the rapidly
expanding cell therapy market and can be utilized across the continuum of the
high-growth cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The ExPERT family
of products includes: four instruments, the ATx™, STx™, GTx™ and VLx
™; a portfolio of proprietary related processing assemblies or disposables;
and software protocols, all supported by a robust worldwide intellectual
property portfolio. By providing our partners with the right technology
platform, as well as scientific, technical and regulatory support, we aim to
guide them on their journey to transform human health. Learn more at
maxcyte.com (https://maxcyte.com/) and follow us on X
(https://twitter.com/MaxCyte_info) (formerly Twitter) and LinkedIn
(https://www.linkedin.com/company/maxcyte-inc-/) .
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Stanley Erck
2 Reason for the notification
a) Position/status Non-Executive Director
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name MaxCyte, Inc.
b) LEI 54930053YHXULRFCU991
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Common Stock of $0.01 each
Identification code US57777K1060
b) Nature of the transaction Exercise of Options over common stock
c) Price(s) and volume(s)
Exercise Price(s) Volume(s)
$0.040 17,922
d) Aggregated information
- Aggregated volume 17,922
- Price $0.040
e) Date of the transaction 3 September 2024
f) Place of the transaction US Stock Exchange, Nasdaq
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Stanley Erck
2 Reason for the notification
a) Position/status Non-Executive Director
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name MaxCyte, Inc.
b) LEI 54930053YHXULRFCU991
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Common Stock of $0.01 each
Identification code US57777K1060
b) Nature of the transaction Sale of common stock
c) Price(s) and volume(s)
Exercise Price(s) Volume(s)
$4.0400 1283
$4.0500 867
$4.0550 75
$4.0600 1277
$4.0650 547
$4.0700 2471
$4.0800 2030
$4.0850 525
$4.0900 2100
$4.0950 281
$4.1000 2679
$4.1100 372
$4.1150 82
$4.1250 69
$4.1300 365
$4.1350 250
$4.1400 894
$4.1450 201
$4.1500 100
$4.1550 32
$4.2100 101
$4.2200 200
$4.2400 100
$4.2500 412
$4.2600 100
$4.2700 200
$4.2800 1
$4.2900 200
$4.3000 108
d) Aggregated information
- Aggregated volume 17,922
- Price $4.0978
e) Date of the transaction 3 September 2024
f) Place of the transaction US Stock Exchange, Nasdaq
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Stanley Erck
2 Reason for the notification
a) Position/status Non-Executive Director
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name MaxCyte, Inc.
b) LEI 54930053YHXULRFCU991
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Common Stock of $0.01 each
Identification code US57777K1060
b) Nature of the transaction Exercise of Options over common stock
c) Price(s) and volume(s)
Exercise Price(s) Volume(s)
$0.040 29,767
d) Aggregated information
- Aggregated volume 29,767
- Price $0.040
e) Date of the transaction 4 September 2024
f) Place of the transaction US Stock Exchange, Nasdaq
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Stanley Erck
2 Reason for the notification
a) Position/status Non-Executive Director
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name MaxCyte, Inc.
b) LEI 54930053YHXULRFCU991
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Common Stock of $0.01 each
Identification code US57777K1060
b) Nature of the transaction Sale of common stock
c) Price(s) and volume(s)
Exercise Price(s) Volume(s)
$3.9000 416
$3.9050 445
$3.9100 1060
$3.9150 3925
$3.9200 5733
$3.9250 250
$3.9300 501
$3.9400 2267
$3.9450 400
$3.9500 600
$3.9550 200
$3.9600 500
$3.9650 200
$3.9700 632
$3.9800 1400
$4.0000 415
$4.0100 300
$4.0200 3544
$4.0300 1637
$4.0350 1620
$4.0400 500
$4.0500 3159
$4.0700 63
d) Aggregated information
- Aggregated volume 29,767
- Price $3.9686
e) Date of the transaction 4 September 2024
f) Place of the transaction US Stock Exchange, Nasdaq
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHEAKNKEEALEFARecent news on MaxCyte
See all newsREG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - First Quarter 2025 Financial Results
AnnouncementREG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Total Voting Rights
AnnouncementREG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Filing of definitive proxy statement
AnnouncementREG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Holding(s) in Company
AnnouncementREG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Holding(s) in Company
Announcement